Legal challenges against pharmaceutical companies are raising serious questions about how drug companies structure their deals and pricing arrangements. Recent settlements and lawsuits suggest that courts and regulators are scrutinizing everything from pricing transparency to how companies negotiate discounts—and they’re not finding things entirely above board. The Federal Trade Commission’s February 2026 settlement with Express Scripts over artificially inflated insulin prices, which is expected to reduce patient out-of-pocket costs by up to $7 billion over a decade, serves as a stark example of how deal structures that seemed legitimate to corporations have triggered major government intervention.
These legal challenges are coming from multiple directions: federal agencies, state attorneys general, and companies suing back against new regulations. What unites them is a fundamental question about whether current pharmaceutical deal structures serve patients or primarily benefit corporations at the expense of public health. For entrepreneurs and business leaders in the health tech space, understanding these challenges isn’t just about regulatory compliance—it’s about recognizing that the pharmaceutical business model itself is under pressure.
Table of Contents
- Why Are Regulators Targeting Drug Pricing Arrangements?
- The Pattern of Price-Fixing Settlements Reveals Systemic Issues
- New State Laws Are Forcing Companies to Challenge Their Business Model
- What These Challenges Mean for Pharmaceutical Deal Structure Going Forward
- The Generic Drug Market Remains Particularly Vulnerable to Legal Challenge
- How Transparency Laws Are Reshaping Deal Requirements
- The Future of Pharmaceutical Deals Depends on Alignment With Public Health Goals
- Conclusion
Why Are Regulators Targeting Drug Pricing Arrangements?
Drug companies traditionally structure deals in ways that maximize profits while appearing to comply with regulations. The Express Scripts settlement reveals how this works in practice: the company allegedly inflated insulin prices through its deal arrangements, driving up costs for patients even as the company claimed to be providing access. This wasn’t a violation buried in complex language—it was a fundamental misalignment between what the deal purported to do and what it actually accomplished.
The FTC’s enforcement action signals that regulators are no longer satisfied with deal structures that technically follow the letter of the law while undermining its spirit. The agency specifically targeted pricing mechanisms that artificially inflated costs, suggesting that future regulatory scrutiny will focus on whether deal terms actually serve the intended purpose of patient access. For companies designing pharmaceutical agreements, this means that economic incentives embedded in contract language are now fair game for regulatory review.
The Pattern of Price-Fixing Settlements Reveals Systemic Issues
The Bausch and Lannett settlement demonstrates that pricing problems aren’t limited to individual companies or isolated incidents. New York’s Attorney General, along with 47 states, secured $17.85 million from Bausch and Lannett for a generic drug price-fixing scheme that ran from May 1, 2009 through December 31, 2019—a decade-long arrangement. This wasn’t an accidental pricing discrepancy; it was a coordinated effort to keep prices artificially high.
What’s particularly notable is that this settlement follows earlier agreements with other companies like Apotex and Heritage, totaling $49.1 million combined. The pattern suggests that price-fixing among generic drug manufacturers may have been more widespread than previously acknowledged. For investors and entrepreneurs, this raises a critical warning: regulatory bodies are treating pharmaceutical pricing as an antitrust matter, not just a competitive business practice. Companies operating in this space should expect that deal terms involving competitors or coordinated pricing will attract intense scrutiny.
New State Laws Are Forcing Companies to Challenge Their Business Model
Washington State’s 340B drug pricing transparency law, set to take effect in June 2026, has prompted major pharmaceutical companies including Novartis and AbbVie to sue the state. AbbVie specifically warned that the law could cost the company “tens of millions of dollars in unrecoverable discounts,” suggesting that the current 340B discount structure—which runs approximately 60 percent of market value—depends on opacity about how discounts are actually applied. This legal challenge reveals a core tension: companies have built their profitability assumptions on deal arrangements that lack transparency.
When states mandate transparency, those arrangements become economically untenable. For entrepreneurs building health tech platforms that interact with pharmaceutical pricing, this suggests that the current opaque system may not last. The business opportunity lies in building tools that make transparent pricing sustainable, not in defending the status quo.
What These Challenges Mean for Pharmaceutical Deal Structure Going Forward
The cumulative effect of these settlements and challenges is a fundamental shift in how pharmaceutical deals will need to be structured. Companies can no longer rely on complex arrangements that obscure pricing or create perverse incentives. The Express Scripts settlement demonstrates that the FTC is willing to pursue cases where deal terms drive prices up rather than down, even for medications like insulin where patient harm is quantifiable.
For startups working in pharmaceutical supply chain management or drug pricing, this presents both a constraint and an opportunity. The constraint is clear: deal structures that benefit corporations at patient expense will face legal challenges. The opportunity is that companies will need better tools for structuring deals transparently. Businesses that help pharmaceutical companies design pricing arrangements that are both competitive and defensible will be valuable as the industry adjusts to new regulatory expectations.
The Generic Drug Market Remains Particularly Vulnerable to Legal Challenge
Generic drugs, which are intended to reduce medication costs through competition, have become a flashpoint for legal action. The pattern of settlements against generic manufacturers suggests this market segment has structural vulnerabilities. Connecticut will host the first major trial on generic drug price-fixing in late 2026, which will likely establish important precedent about how courts evaluate coordination among generic manufacturers.
The warning here is important: the generic drug market’s economic model—which assumes vigorous price competition—appears to have broken down in some segments. When companies can’t compete on price, they find other ways to coordinate. Courts and regulators are increasingly willing to prosecute these arrangements. For companies involved in generic manufacturing or distribution, deal terms that appear innocuous on the surface—information sharing, market allocation, or coordinated pricing announcements—may be viewed as antitrust violations under current enforcement trends.
How Transparency Laws Are Reshaping Deal Requirements
The Washington State law requiring transparency in 340B discounts represents a new regulatory direction that other states are likely to follow. Instead of allowing pharmaceutical companies to negotiate privately with hospitals and clinics about discount terms, the law requires disclosure of how those discounts are calculated and applied. This transparency requirement forces companies to restructure deals in ways that would have been unthinkable five years ago.
From a business perspective, transparency laws eliminate the competitive advantage that companies previously gained from opaque pricing. Novartis and AbbVie’s legal challenge suggests they view this as an existential threat to their current deal structure. However, the trend toward transparency is likely irreversible. Companies that adapt their business models to operate profitably within transparent pricing frameworks will have a competitive advantage over those fighting the trend.
The Future of Pharmaceutical Deals Depends on Alignment With Public Health Goals
The legal challenges facing pharmaceutical companies suggest that the era of deal structures optimized purely for corporate profit is ending. Regulators and courts are increasingly evaluating whether pharmaceutical arrangements serve public health objectives.
The Express Scripts settlement—reducing patient out-of-pocket insulin costs by billions—reflects the outcome that regulators now expect to see from major pharmaceutical deals. For entrepreneurs building businesses around pharmaceutical distribution, pricing, or supply chain management, the strategic implication is clear: future deal structures will need to demonstrate public health benefit, not just corporate profitability. Companies that can design arrangements where lower costs for patients and transparency are the foundation of profitability, rather than obstacles to it, will thrive in the next decade.
Conclusion
Legal challenges to pharmaceutical deal terms are fundamentally reshaping how the industry structures agreements. From the FTC’s Express Scripts settlement to state attorneys general pursuing price-fixing cases to new transparency laws, the regulatory message is consistent: deal terms that artificially inflate prices or lack transparency will face legal consequences. The pattern of enforcement suggests that this isn’t temporary regulatory zeal but a structural shift in how courts and agencies evaluate pharmaceutical arrangements.
For entrepreneurs and business leaders, these challenges represent both a constraint and an opportunity. The constraint is that opaque, profit-maximizing deal structures face increasing legal risk. The opportunity is in building new business models that deliver both corporate profitability and demonstrable public health benefits. Companies that innovate within this new regulatory environment—rather than fighting it—will define the next generation of pharmaceutical business practices.